

**Online supplementary table S1. Proportion of cases treated with bedaquiline per country/state during the study period out of 428 confirmed MDR-/XDR TB cases.**

Country	Number of sites	Cases included in the present study, <i>n</i> (% of the total cases; n=428)	Proportion of cases treated with BDQ during the study period out of the total cases in the same Country/State (%)	MDR-TB, <i>n</i> (%) (n=233)	XDR-TB <i>n</i> (%) (n=195)	Known outcome <i>n</i> (%) (n=247)
Argentina	1	1 (0.2)	100%	-	1 (0.5)	1 (0.4)
Australia (State of Victoria)	1	4 (0.9)	100%	2 (0.9)	2 (1.0)	1 (0.4)
Belarus	2	30 (7.0)	16.1%	9 (3.9)	21 (10.8)	-
Belgium	1	7 (1.6)	53.8%	6 (2.6)	1 (0.5)	2 (0.8)
Greece	2	2 (0.5)	100%	-	2 (1.0)	2 (0.8)
India	2	21 (4.9)	40.4%	8 (3.4)	13 (6.7)	17 (6.9)
Italy	4	26 (6.1)	66.7%	17 (7.3)	9 (4.6)	9 (3.6)
Netherlands	1	5 (1.2)	71.4%	3 (1.3)	2 (1.0)	3 (1.2)
Peru	1	15 (3.5)	100%	15 (6.4)	-	10 (4.1)
Portugal	1	1 (0.2)	50%	-	1 (0.5)	1 (0.4)
Russian Federation	2	120 (28.0) of whom: - Moscow City 90 (21.0) - Arkhangelsk Oblast 30 (7.0)	8.8% of whom: - Moscow City 38.1% - Arkhangelsk Oblast 100%	53 (22.8)	67 (34.4)	85 (34.4)
South Africa	3	190 (44.4)	11.6%	117 (50.2)	73 (37.4)	113 (45.8)
Spain	2	2 (0.5)	100%	2 (0.9)	-	-
Sweden	1	3 (0.7)	27.3%	1 (0.4)	2 (1.0)	3 (1.2)
United Kingdom	1	1 (0.2)	7.7%	-	1 (0.5)	-

MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis; Bdq: bedaquiline